KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Gains from Investment Securities (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Gains from Investment Securities data on record, last reported at $9.7 million in Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 161.78% year-over-year to $9.7 million; the TTM value through Dec 2025 reached -$12.2 million, down 243.53%, while the annual FY2025 figure was $7.4 million, 140.22% up from the prior year.
  • Gains from Investment Securities reached $9.7 million in Q4 2025 per EW's latest filing, up from -$5.7 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $96.6 million in Q4 2021 and bottomed at -$102.6 million in Q2 2021.
  • Average Gains from Investment Securities over 5 years is -$4.0 million, with a median of -$2.6 million recorded in 2021.
  • Peak YoY movement for Gains from Investment Securities: crashed 1136.36% in 2021, then surged 1140.0% in 2022.
  • A 5-year view of Gains from Investment Securities shows it stood at $96.6 million in 2021, then tumbled by 102.38% to -$2.3 million in 2022, then tumbled by 265.22% to -$8.4 million in 2023, then tumbled by 86.9% to -$15.7 million in 2024, then soared by 161.78% to $9.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $9.7 million in Q4 2025, -$5.7 million in Q3 2025, and -$15.7 million in Q4 2024.